Does resveratrol work? What is left of the claim
Reviewed 28 sourcesPublished by PepVault
Does resveratrol work? The sirtuin story, the failed mouse lifespan tests, the drug that was stopped and what human trials measured, as of November 2026.

- Last reviewed
- Sources
- 28
- Questions
- 9
- Compounds
- 2
The short answer
Not for what made it famous. Resveratrol lengthened life in yeast and in mice on a high-calorie diet, but the US aging institute's strict mouse program found no lifespan gain, twice. In people, pooled trials show no real weight loss and a blood-pressure drop of about 8 mmHg in type 2 diabetes, and in one trial it blunted the gains older men got from exercise.
Evidence: High for a blood-pressure drop in people with type 2 diabetes, mixed for blood sugar; no human evidence for longer life, and the strict mouse lifespan tests were negative.

Where did the resveratrol longevity claim come from?
It started in yeast. In 2003 David Sinclair's lab at Harvard and scientists at BIOMOL, a lab-supply company, reported that resveratrol, a plant compound (a polyphenol) in red grape skins, switched on sirtuins and extended the lifespan of baker's yeast by 70%1. Sirtuins are enzymes that strip chemical tags off other proteins, and they were then a leading explanation for why eating less makes many animals live longer. A pill that flipped the same switch would be calorie restriction without the hunger.
In 2006 the claim reached mammals. One-year-old mice on a high-calorie diet got about 22 mg of resveratrol per kg of body weight a day, and their risk of death fell by 31% against high-calorie mice without it, close to the risk of mice on a normal diet2. They stayed fat: body weight did not differ between 18 and 24 months of age. The paper ran in Nature, and red wine headlines followed.
Money followed too. On April 22, 2008, GlaxoSmithKline agreed to buy Sirtris Pharmaceuticals, a company developing sirtuin activators as drugs, for about $720 million, or $22.50 a share3.

Does resveratrol really activate sirtuins?
Only under particular conditions, and the first evidence leaned on a dye. The 2003 test used a protein fragment with a fluorescent tag attached, sold as the Fluor de Lys kit by the company that co-wrote the paper15. In 2005 two labs showed that resveratrol sped up the human sirtuin SIRT1 about eightfold with the tagged fragment and not at all without the tag45. One of them also found no effect on yeast lifespan in three strains4.
In 2010 Pfizer scientists tested resveratrol and three Sirtris compounds against natural, untagged proteins and concluded that none of them directly activates SIRT16. Sinclair's group answered in 2013: SIRT1 does respond to these molecules, but only with certain natural proteins whose shape resembles the dye, through a single spot on the enzyme7. Both findings stand. The sirtuin effect is real in a dish, narrower than the 2003 story, and it has never been shown to explain a lifespan gain in a mammal.
Did resveratrol make mice live longer?
Only mice that were overeating. On a normal diet, resveratrol started at 12 months made old mice healthier (fewer cataracts, more flexible arteries, better coordination) but they did not live longer; the paper's own title says so8. Then the National Institute on Aging's Interventions Testing Program, which runs each compound at three sites in genetically mixed mice so a single lab's quirks cannot drive the result, tested it twice: at two doses in food, and lifelong from 4 months of age. Neither changed lifespan in males or females910.
| Test | Who | Lifespan result |
|---|---|---|
| Yeast, 20031 | Baker's yeast | +70% |
| Mice on a high-calorie diet, 20062 | Male mice from 1 year old | Risk of death down 31% against high-calorie controls |
| Mice on a normal diet, 20088 | Mice from 12 months old | No longer life, better health markers |
| NIA program, 20119 | Mixed mice, 3 sites, 2 doses | No effect, either sex |
| NIA program, 201310 | Mixed mice from 4 months old | No effect, either sex |
| People, 201422 | 783 Italians aged 65+, 9 years | Dietary resveratrol not linked to death rates |
Species note: every lifespan gain in the table is in yeast or overfed mice. No trial has tested resveratrol for lifespan in people.
What happened to the drug version, SRT501?
It was stopped. SRT501 was Sirtris's high-dose resveratrol, given as 5 g a day. In a phase 2 trial sponsored by Sirtris, by then a GSK company, 24 people with multiple myeloma, a blood cancer, took it alone and, if the cancer grew, with the cancer drug bortezomib. The registry lists the trial as terminated, ending in November 2010, and its posted results show serious kidney events in several patients: acute kidney failure in 3, kidney failure in 2 and kidney impairment in 1, of the 2411.
What about the resveratrol researcher who faked data?
That was a different lab and a different line of work. On January 11, 2012, the University of Connecticut Health Center announced that a three-year investigation had found Dipak Das, a heart researcher known for resveratrol papers, guilty of 145 counts of fabricating and falsifying data; it notified 11 journals and turned down $890,000 in federal grants awarded to him12. Journals then retracted his papers. One notice, in the Journal of Cellular and Molecular Medicine, retracts a 2006 resveratrol heart study for fabricated western blot data found in that investigation13, and a PubMed search for his retracted papers that mention resveratrol returns nine28.
His work was on resveratrol and the heart in rodents, not on sirtuins and lifespan. The fraud removed a pile of positive rat studies from the record; it did not touch the yeast or mouse lifespan papers above.
What did resveratrol do in human trials?
Small trials pointed both ways, and pooled trials settle on small effects in people who are already metabolically unwell. In 11 obese men, 150 mg a day for 30 days lowered systolic blood pressure by about 5 mmHg and lowered liver fat, much like calorie restriction14. Then 24 obese men took 1,500 mg a day for 4 weeks and nothing changed: not insulin sensitivity, fat, blood pressure or inflammation15. In nonobese postmenopausal women (15 on resveratrol, 14 on placebo), 75 mg a day for 12 weeks changed nothing, not even SIRT1 in their muscle16.
| Outcome | Pooled result | Source |
|---|---|---|
| Blood pressure, all adults | Systolic −2.5 mmHg, not significant (17 trials) | Fogacci 201917 |
| Blood pressure, type 2 diabetes | Systolic −8.0 and diastolic −3.6 mmHg, high-certainty evidence | Umbrella review 202618 |
| Glucose, people with diabetes | Lower fasting glucose, insulin and HbA1c (3-month average blood sugar); 11 trials, 388 people in all | Liu 201419 |
| Glucose, people with diabetes, newer pooling | No significant effect on fasting glucose or HbA1c across 10 meta-analyses | Umbrella review 202620 |
| Glucose, people without diabetes | No effect | Liu 201419 |
| Body weight, overweight adults | −1.4 kg, not significant (23 trials, 1,005 people) | Setayesh 202621 |
| Waist | −1.9 cm (23 trials); −0.8 cm, high certainty (umbrella) | 2118 |
The blood-pressure drop in type 2 diabetes is the firmest result. The blood-sugar signal is contested: the 2014 pooling found lower HbA1c, a 2026 review of ten meta-analyses did not1920. Added to nicotinamide riboside in 90 people with poor leg circulation, resveratrol added nothing to the walking gain27.
PepVault's weight log charts your own weigh-ins over time, so a change of a kilogram or two, the size the trials pooled, shows up as a line rather than a guess. Track your weight in PepVault
Does resveratrol cancel out exercise?
In one trial in older men, it blunted part of it. Twenty-seven inactive men aged about 65 did 8 weeks of high-intensity training with 250 mg of resveratrol or placebo a day. Fitness (maximal oxygen uptake) rose 45% more in the placebo group, blood pressure fell only on placebo (−4.8 mmHg), and resveratrol wiped out the training's improvement in LDL cholesterol and triglycerides23. A sister paper from the same trial found that training improved the muscle's energy machinery and resveratrol added nothing24.
That is one trial in one group, and it has not been repeated at scale. It is still the clearest human sign that taking resveratrol alongside training is not free, which matters because resveratrol has been proposed as an exercise mimic24.
Commonly reported: nothing you can feel day to day at the doses most trials used; in a dosing study, mild to moderate stomach and bowel upset at 2.5 and 5 g a day26.
How much resveratrol does the body absorb?
Most of it, and then the body changes almost all of it at once. In six volunteers given a radio-labelled 25 mg dose, at least 70% was absorbed, but only trace amounts of unchanged resveratrol (under 5 ng/mL) reached the blood; the gut wall and liver rapidly attach sulfate and sugar groups to it, and the labelled material stayed in the blood with a half-life of about 9 hours25. Bioavailability, the share of a dose that reaches the blood unchanged, is therefore very low. Even at gram doses, its sulfate and glucuronide forms outweighed resveratrol itself in the blood by up to 20-fold26.
This is the core of the mouse-to-human gap. Dish experiments used resveratrol itself at levels a capsule does not reach in a person, and whether its breakdown forms do the same job is not settled.
Is resveratrol worth taking?
For a longer life, the evidence as of November 2026 says no: the lifespan gains were in yeast and overfed mice, and the strict mouse tests were negative. For blood pressure in type 2 diabetes there is a repeated signal; for blood sugar the pooled reviews disagree. For weight there is next to nothing, and for anyone training to get fitter, one trial suggests it can take away part of the gain.
The trials ran from 75 mg to 1,500 mg a day for weeks to months, with gram doses in dosing and cancer studies; those are the doses studied, not a recommendation. If you take a prescription medicine, adding resveratrol is a decision to make with your prescriber.
Resveratrol is in PepVault's library. Add it to a protocol as an oral supplement and the app logs each day's capsule and can remind you at the time you set. Log it in PepVault
Sources
- Howitz KT et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003. PubMed 12939617
- Baur JA et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006. PubMed 17086191
- GlaxoSmithKline plc. GSK to acquire Sirtris Pharmaceuticals (press release, April 22, 2008), SEC Form 6-K. sec.gov
- Kaeberlein M et al. Substrate-specific activation of sirtuins by resveratrol. J Biol Chem. 2005. PubMed 15684413
- Borra MT et al. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem. 2005. PubMed 15749705
- Pacholec M et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem. 2010. PubMed 20061378
- Hubbard BP et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science. 2013. PubMed 23471411
- Pearson KJ et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008. PubMed 18599363
- Miller RA et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci. 2011. PubMed 20974732
- Strong R et al. Evaluation of resveratrol, green tea extract, curcumin, oxaloacetic acid, and medium-chain triglyceride oil on life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci. 2013. PubMed 22451473
- ClinicalTrials.gov NCT00920556. SRT501 alone or with bortezomib in multiple myeloma (Sirtris, a GSK company), results posted 2019. clinicaltrials.gov
- UConn Today. Scientific journals notified following research misconduct investigation. University of Connecticut, January 11, 2012. today.uconn.edu
- Retracted: Differential proteomic profiling to study the mechanism of cardiac pharmacological preconditioning by resveratrol (retraction notice). J Cell Mol Med. 2012. PubMed 23189335
- Timmers S et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011. PubMed 22055504
- Poulsen MM et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 2013. PubMed 23193181
- Yoshino J et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 2012. PubMed 23102619
- Fogacci F et al. Effect of resveratrol on blood pressure: a systematic review and meta-analysis of randomized, controlled, clinical trials. Crit Rev Food Sci Nutr. 2019. PubMed 29359958
- Sun JN et al. Effects of resveratrol supplementation on multiple health outcomes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials. Nutr J. 2026. PubMed 41987155
- Liu K et al. Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr. 2014. PubMed 24695890
- Ghalichi F et al. The effects of resveratrol on glycemic indices and lipid profile in patients with type 2 diabetes: an umbrella review and meta-analysis. Daru. 2026. PubMed 42268476
- Setayesh A et al. The effect of resveratrol supplementation on anthropometric indices, adiponectin and leptin levels in individuals with overweight and obesity: a meta-analysis. Int J Obes. 2026. PubMed 41455817
- Semba RD et al. Resveratrol levels and all-cause mortality in older community-dwelling adults. JAMA Intern Med. 2014. PubMed 24819981
- Gliemann L et al. Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men. J Physiol. 2013. PubMed 23878368
- Olesen J et al. Exercise training, but not resveratrol, improves metabolic and inflammatory status in skeletal muscle of aged men. J Physiol. 2014. PubMed 24514907
- Walle T et al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004. PubMed 15333514
- Brown VA et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010. PubMed 20935227
- McDermott MM et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nat Commun. 2024. PubMed 38871717
- PubMed. Retracted publications by Das DK on resveratrol (search run November 20, 2026). pubmed.ncbi.nlm.nih.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.